1. Treatment of advanced malignant melanoma with interferon alpha and etretinate
- Author
-
Ann Nelstrop, Gordon J. S. Rustin, Steven T. de Garis, and Stanley Dische
- Subjects
Male ,medicine.medical_specialty ,Skin Neoplasms ,Vindesine ,medicine.medical_treatment ,Alpha interferon ,Etretinate ,Gastroenterology ,Interferon ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Melanoma ,Interferon alfa ,Chemotherapy ,business.industry ,Immunotherapy ,Middle Aged ,medicine.disease ,Dacarbazine ,Oncology ,Interferon Type I ,Immunology ,Female ,business ,medicine.drug - Abstract
The combination of recombinant human interferon alpha A 9 MU daily intramuscularly and etretinate 50 mg daily orally was given to 25 patients with progressive advanced, metastatic melanoma. The treatment was well tolerated. Partial responses were seen in three (12%) patients lasting from 2 to 8 months. A further partial response was seen in one of three patients when they were given vindesine and DTIC whilst they continued receiving interferon and etretinate.
- Published
- 1988
- Full Text
- View/download PDF